Tritoqualine - H4Orphan Pharma
Latest Information Update: 28 Oct 2021
Price :
$50 *
At a glance
- Originator H4Orphan Pharma
- Class Anti-inflammatories; Antiallergics; Antipruritics; Hepatoprotectants; Isoquinolines; Small molecules
- Mechanism of Action Histamine H4 receptor agonists; Interleukin-8 expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in France
- 22 May 2019 Chemical structure information added
- 21 Sep 2017 H4 Orphan Pharma has patent protection for the use of an h4 agonist molecule for the treatment of idiopathic pulmonary fibrosis worldwide